Dimercaprol
FDA-approved product (injectable, injection), marketed as Bal.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Dimercaprol. Its therapeutic class is shown instead.
- WHO therapeutic group
- Antidotes
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Dimercaprol, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA15.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli13.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae8.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis16.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dimercaprol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pitavastatin SodiumExisting use: Abnormal circulating lipid concentration, Cardiovascular disease, Familial hypercholesterolemia and 2 more66.8% AI-predicted activityagainst M. tuberculosis18 registered studies
- AmisulprideExisting use: Nausea and vomiting, Post operative nausea and vomiting, Psychosis66.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ItraconazoleExisting use: Aspergillosis, Blastomycosis, Candidiasis and 4 more66.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Dantrolene SodiumExisting use: Cerebral palsy, Fever, Malignant hyperthermia and 4 more66.6% AI-predicted activityagainst M. tuberculosis12 registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma66.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Methixene HydrochlorideExisting use: Parkinson disease66.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Cisapride MonohydrateExisting use: Gastrointestinal disease66.5% AI-predicted activityagainst M. tuberculosis5 registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more66.3% AI-predicted activityagainst M. tuberculosis10 registered studies
- QuazepamExisting use: Insomnia66.3% AI-predicted activityagainst M. tuberculosis1 registered study
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TerconazoleExisting use: Triazole derivatives66.2% AI-predicted activityagainst M. tuberculosis10 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma66.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057
NCT01587807 · start 2012-03-28
Registered record
- Registry ID
- NCT01587807
- Conditions
- Respiratory Disorders
- Interventions
- GSK1995057; bronchoalveolar lavage; LPS; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-03-28
- Completion
- 2012-11-19
- Enrolment
- 53
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRespiratory DisordersInterventionGSK1995057; bronchoalveolar lavage; LPS; PlaceboPhasePhase 1Registry statusCompletedInduced Sputum Versus Bronchoscopy in Smear Negative Pulmonary Tuberculosis
NCT01011543 · start 2009-08
Registered record
- Registry ID
- NCT01011543
- Conditions
- Pulmonary Tuberculosis
- Interventions
- Diagnostic techniques in pulmonary tuberculosis
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2009-08
- Completion
- 2015-12
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary TuberculosisInterventionDiagnostic techniques in pulmonary tuberculosisPhaseNot applicableRegistry statusCompletedTransbronchial Needle Aspiration in the Diagnosis of Peripheral Pulmonary Malignancy
NCT00917137 · start 2008-07
Registered record
- Registry ID
- NCT00917137
- Conditions
- Pulmonary Nodule; Pulmonary Mass
- Interventions
- TBNA + transbronchial lung biopsy + bronchial washing
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2008-07
- Completion
- 2010-06
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Nodule; Pulmonary MassInterventionTBNA + transbronchial lung biopsy + bronchial washingPhaseNot recordedRegistry statusCompletedDiagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples
NCT01430663 · start 2007-04
Registered record
- Registry ID
- NCT01430663
- Conditions
- Invasive Aspergillosis
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-04
- Completion
- 2011-02
- Enrolment
- 87
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInvasive AspergillosisInterventionNot recordedPhaseNot recordedRegistry statusCompletedAnalysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis
NCT00001541 · start 1996-04
Registered record
- Registry ID
- NCT00001541
- Conditions
- Inflammation; Vasculitis; Wegener's Granulomatosis
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 1996-04
- Completion
- 2003-01
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInflammation; Vasculitis; Wegener's GranulomatosisInterventionNot recordedPhaseNot recordedRegistry statusCompleted